These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 23047784)

  • 1. Active surveillance of postmarket medical product safety in the Federal Partners' Collaboration.
    Robb MA; Racoosin JA; Worrall C; Chapman S; Coster T; Cunningham FE
    Med Care; 2012 Nov; 50(11):948-53. PubMed ID: 23047784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The U.S. Food and Drug Administration's Mini-Sentinel program: status and direction.
    Platt R; Carnahan RM; Brown JS; Chrischilles E; Curtis LH; Hennessy S; Nelson JC; Racoosin JA; Robb M; Schneeweiss S; Toh S; Weiner MG
    Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():1-8. PubMed ID: 22262586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.
    Zhou W; Pool V; Iskander JK; English-Bullard R; Ball R; Wise RP; Haber P; Pless RP; Mootrey G; Ellenberg SS; Braun MM; Chen RT
    MMWR Surveill Summ; 2003 Jan; 52(1):1-24. PubMed ID: 12825543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Food and Drug Administration's Post-Licensure Rapid Immunization Safety Monitoring program: strengthening the federal vaccine safety enterprise.
    Nguyen M; Ball R; Midthun K; Lieu TA
    Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():291-7. PubMed ID: 22262619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design considerations, architecture, and use of the Mini-Sentinel distributed data system.
    Curtis LH; Weiner MG; Boudreau DM; Cooper WO; Daniel GW; Nair VP; Raebel MA; Beaulieu NU; Rosofsky R; Woodworth TS; Brown JS
    Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():23-31. PubMed ID: 22262590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Opening Pandora's pillbox: using modern information tools to improve drug safety.
    Gottlieb S
    Health Aff (Millwood); 2005; 24(4):938-48. PubMed ID: 16012136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advancing the science for active surveillance: rationale and design for the Observational Medical Outcomes Partnership.
    Stang PE; Ryan PB; Racoosin JA; Overhage JM; Hartzema AG; Reich C; Welebob E; Scarnecchia T; Woodcock J
    Ann Intern Med; 2010 Nov; 153(9):600-6. PubMed ID: 21041580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The US Food and Drug Administration's Sentinel Initiative: expanding the horizons of medical product safety.
    Robb MA; Racoosin JA; Sherman RE; Gross TP; Ball R; Reichman ME; Midthun K; Woodcock J
    Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():9-11. PubMed ID: 22262587
    [No Abstract]   [Full Text] [Related]  

  • 9. Postmarketing surveillance of medical devices using Medicare claims.
    Malenka DJ; Kaplan AV; Sharp SM; Wennberg JE
    Health Aff (Millwood); 2005; 24(4):928-37. PubMed ID: 16012135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FDA's expanding postmarket authority to monitor and publicize food and consumer health product risks: the need for procedural safeguards to reduce "transparency" policy harms in the post-9/11 regulatory environment.
    Roller ST; Pippins RR; Ngai JW
    Food Drug Law J; 2009; 64(3):577-98. PubMed ID: 19999646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Geographic proximity of HRSA, VA, and DOD clinics: opportunities for interagency collaboration to improve quality.
    Brownell J; Xierali I; Herrera AP; Calvo A
    J Health Care Poor Underserved; 2012 Aug; 23(3 Suppl):125-35. PubMed ID: 22864493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A beneficial side effect of the Medicare drug benefit.
    Platt R; Ommaya A
    N Engl J Med; 2005 Dec; 353(26):2742-3. PubMed ID: 16382059
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical and behavioral characteristics of adults receiving medical care for HIV infection --- Medical Monitoring Project, United States, 2007.
    Blair JM; McNaghten AD; Frazier EL; Skarbinski J; Huang P; Heffelfinger JD
    MMWR Surveill Summ; 2011 Sep; 60(11):1-20. PubMed ID: 21881551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A policy framework for public health uses of electronic health data.
    McGraw D; Rosati K; Evans B
    Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():18-22. PubMed ID: 22262589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statistical approaches to group sequential monitoring of postmarket safety surveillance data: current state of the art for use in the Mini-Sentinel pilot.
    Cook AJ; Tiwari RC; Wellman RD; Heckbert SR; Li L; Heagerty P; Marsh T; Nelson JC
    Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():72-81. PubMed ID: 22262595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of postmarketing surveillance in contemporary medicine.
    Woodcock J; Behrman RE; Dal Pan GJ
    Annu Rev Med; 2011; 62():1-10. PubMed ID: 20809798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of serious adverse drug reactions: a proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturers.
    Bennett CL; Nebeker JR; Yarnold PR; Tigue CC; Dorr DA; McKoy JM; Edwards BJ; Hurdle JF; West DP; Lau DT; Angelotta C; Weitzman SA; Belknap SM; Djulbegovic B; Tallman MS; Kuzel TM; Benson AB; Evens A; Trifilio SM; Courtney DM; Raisch DW
    Arch Intern Med; 2007 May; 167(10):1041-9. PubMed ID: 17533207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medical device vigilance at FDA.
    Gross TP; Kessler LG
    Stud Health Technol Inform; 1996; 28():17-24. PubMed ID: 10164091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-World Data, Advanced Analytics, and the Evolution of Postmarket Drug Safety Surveillance.
    Dal Pan GJ
    Clin Pharmacol Ther; 2019 Jul; 106(1):28-30. PubMed ID: 30958565
    [No Abstract]   [Full Text] [Related]  

  • 20. Change in use of gadolinium-enhanced magnetic resonance studies in kidney disease patients after US Food and Drug Administration warnings: a cross-sectional study of Veterans Affairs Health Care System data from 2005-2008.
    Kim KH; Fonda JR; Lawler EV; Gagnon D; Kaufman JS
    Am J Kidney Dis; 2010 Sep; 56(3):458-67. PubMed ID: 20580477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.